Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile
03/06/2023 14:11
June 3 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* PRELIMINARY ONGOING RESULTS WITH CYT-0851 IN COMBINATION
WITH
CAPECITABINE OR GEMCITABINE IN ADVANCED SOLID TUMORS SHOW EARLY
CLINICAL ACTIVITY AND GENERALLY WELL TOLERATED SAFETY PROFILE
* CYTEIR THERAPEUTICS INC SAYS ENROLLMENT IN PHASE 1 DOSE
ESCALATION STUDY CONTINUES WITH PRELIMINARY DATA EXPECTED IN
MID-2023
Source text for Eikon: ID:nBw8dBQgxa
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile